A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

A Phase 2, Long-term Extension Study of the Safety and Efficacy of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored ORX750 Clinical Trial

This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).

Inclusion Criteria:

• Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1)
• Is willing and able to adhere to additional protocol requirements

Exclusion Criteria:

• Development of any new disease/disorder that in the opinion of the investigator would make the participant unable to continue the study
• Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia